Welcome to our dedicated page for CLXT news (Ticker: CLXT), a resource for investors and traders seeking the latest updates and insights on CLXT stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CLXT's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CLXT's position in the market.
Calyxt, a plant-based synthetic biotechnology company, announced the operational status of its pilot BioFactory production system at its Minnesota headquarters as of January 6, 2022. This milestone, achieved on schedule, aims to enhance the company’s production capabilities by integrating its proprietary PlantSpring technology. CEO Michael A. Carr expressed optimism over customer interest and plans to secure orders for two to four compounds by year-end 2022. The BioFactory is expected to support the rapid prototyping and production of complex plant-derived compounds without traditional agricultural methods.
Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biotechnology company, announced that management will present at the H.C. Wainwright BioConnect Conference on January 10, 2022, at 7:00 a.m. ET. The conference will be held virtually, allowing online viewing of the presentation. Investors can access the webcast via Calyxt's website. For further inquiries or to schedule meetings with management, contact investors@calyxt.com. Calyxt utilizes its PlantSpring™ technology to develop sustainable products.
Calyxt, a plant-based synthetic biotechnology company (Nasdaq: CLXT), has completed a significant milestone in its lab-scale BioFactory manufacturing system, identifying over 15,000 unique chemical signatures. These signatures, including known and uncharacterized molecules, form a library for producing valuable compounds in target markets such as cosmetics, pharmaceuticals, and nutraceuticals. The company is optimizing production processes for these target chemistries and is on track to operationalize its pilot BioFactory by the end of 2021.
Calyxt, a plant-based synthetic biotechnology company (Nasdaq: CLXT), announced the hiring of two key executives: Vijay Gullapalli as Vice President of AI/ML and Data Science, and Pete Ball as Technology Licensing Leader. These roles are critical for advancing Calyxt's strategic direction and enhancing its PlantSpring™ technology platform. Gullapalli brings 25 years of experience in AI and data technology, while Ball has nearly 35 years of legal and licensing expertise. The company aims to help customers create sustainable products using innovative plant-based solutions.
Calyxt, a plant-based synthetic biotechnology company, announced its participation in the 2021 Canaccord Genuity AgriFood Tech Innovation Virtual Forum on December 2, 2021. Management will present at 11:00 a.m. ET and will be available for meetings during the conference. Interested parties can view the presentation and replay on the Investors section of Calyxt's website. Calyxt utilizes its proprietary PlantSpring™ technology to engineer sustainable materials through its BioFactory™ production system, aiming to meet customer sustainability goals.
Calyxt, a synthetic biotechnology company, reported its Q3 2021 financials, showing revenue growth of 48% year-over-year to $7.8 million. The increase was attributed to a shift in product sales from soybean oil to grain. The company also plans to enhance its synthetic biology capabilities with its proprietary PlantSpring technology and BioFactory production system. Notably, Calyxt's net loss improved to $7.3 million, a 23% reduction from the previous year, with a focus on operational efficiencies and strategic partnerships.
Calyxt, Inc. (CLXT) will hold a conference call on November 4, 2021, at 4:30 p.m. EST to discuss its third quarter 2021 results ending September 30, 2021. The call will be led by CEO Michael A. Carr and CFO Bill Koschak, followed by a Q&A session. Interested parties can access the call via a toll-free number or through the company's investor relations website. A replay will be available for 30 days after the event. For more information, visit www.calyxt.com.
Calyxt, Inc. (Nasdaq: CLXT) announced the appointment of Dr. Seth Dobrin, IBM's Global Chief AI Officer, to its Scientific Advisory Board. Dr. Dobrin's expertise in AI and data-driven business solutions is expected to enhance Calyxt's PlantSpringTM platform and BioFactoryTM production system. This strategic initiative aims to accelerate the development of plant-based synthetic biology solutions across various industries. Calyxt believes this integration will improve efficiency and scalability, ultimately helping customers meet sustainability goals.
Calyxt (Nasdaq: CLXT) has launched a strategic initiative focusing on engineering synthetic biology solutions to cater to a broader customer base across industries such as nutraceutical, cosmeceutical, pharmaceutical, and materials. Key components include the integration of its PlantSpring technology platform with the new BioFactory bioreactor, aimed at producing plant-derived compounds sustainably. The company estimates a full cycle from design to pilot production within 36 months, leveraging AI and machine learning for efficiency. Recent developments include a $50 million share issuance program and a partnership for soybean oil production.
Calyxt, the plant-based technology platform company, has announced a research collaboration with a leading global food ingredient manufacturer from Asia to develop an improved soybean that can produce a palm oil alternative. This partnership may generate over $35 million in future aggregate payments if certain conditions are met. The collaboration aims to address sustainability issues related to palm oil while capitalizing on Calyxt's proprietary technology platform, enhancing its partner-driven innovation model.
FAQ
What is the market cap of CLXT (CLXT)?
